rss
Evid Based Med 2002;7:137 doi:10.1136/ebm.7.5.137
  • Therapeutics

Oestrogen plus progestogen increased coronary heart disease and breast cancer events in postmenopausal women

(2002) JAMA 288, 321; Writing Group for the Women’s Health Initiative Investigators.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial.. Jul 17;. :. –33.


 
 QUESTION: In postmenopausal women, what are the risks and benefits of oestrogen plus progestogen use, particularly with respect to coronary heart disease (CHD) events?

Design

Randomised (allocation concealed*), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee),** placebo controlled trial with a mean 5.2 years of follow up.

Setting

40 US clinical centres.

Participants

16 608 postmenopausal women who were 50 to 79 years of age (mean age 63.3 y). Exclusion criteria included probable survival of < 3 years, previous breast cancer or other cancer in the past 10 years, and low haematocrit or platelet counts. Follow up was 96.5%.

Intervention

Women were allocated to 1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (Prempro, Wyeth Ayerst, Philadelphia, PA, USA) …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.